Patient information protected and easily accessed by clinicians
CHALFONT, PA – September 23, 2013 – Genomind, a personalized medicine company in neuropsychiatry, is excited to announce the launch of their new clinician portal.
The new Genomind Portal is a safe, convenient way for clinicians to easily access their patients’ test results from the Genecept™ Assay. The Assay is Genomind’s simple to use, saliva-based test which looks at genetic biomarkers that may affect the type of medication or treatment a doctor would prescribe to patients suffering from psychiatric disorders. The secure site allows clinicians to review and download comprehensive reports via login credentials any time or place, giving flexibility to their busy schedules.
All results are available electronically and can be downloaded directly from the Portal. The Genomind Portal also has the ability to send email and text alerts to advise them of new patient reports which are ready to be viewed. Genomind news and education specific for clinicians who utilize the Genecept™ Assay is also available, making this the central point of electronic communication between Genomind and clinicians who utilize their services.
“We created the Genomind Portal with clinicians in mind. We believe that helping clinicians seamlessly integrate the use of biomarkers in their practices will result in improved care for patients who suffer from psychiatric disorders,” said Scott A. Storrer, President and Chief Executive Officer. “We have been encouraged by the feedback and ease of use clinicians have experienced thus far and look forward to providing this service to clinicians nationwide.”
The Portal is available to all clinicians who utilize the Genecept™ Assay in their practices and institutions. It can be found on the home page of the Genomind website or directly through a link provided to clinicians in their welcome materials.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind